S&P 500   3,135.96 (-0.32%)
DOW   27,909.60 (-0.38%)
QQQ   204.07 (-0.45%)
AAPL   266.92 (-1.40%)
FB   201.34 (+0.14%)
MSFT   151.36 (-0.26%)
GOOGL   1,342.99 (+0.27%)
AMZN   1,749.51 (-0.12%)
CGC   21.29 (+14.16%)
NVDA   212.17 (+0.00%)
MU   46.45 (-3.09%)
BABA   198.74 (-1.56%)
GE   10.99 (-0.99%)
TSLA   339.53 (+1.08%)
T   38.04 (-0.42%)
AMD   38.93 (-1.77%)
ACB   2.62 (+7.82%)
F   9.01 (-0.11%)
PRI   135.35 (-0.24%)
NFLX   302.50 (-1.58%)
BAC   33.51 (-0.48%)
GILD   66.93 (-0.22%)
DIS   146.21 (-0.98%)
S&P 500   3,135.96 (-0.32%)
DOW   27,909.60 (-0.38%)
QQQ   204.07 (-0.45%)
AAPL   266.92 (-1.40%)
FB   201.34 (+0.14%)
MSFT   151.36 (-0.26%)
GOOGL   1,342.99 (+0.27%)
AMZN   1,749.51 (-0.12%)
CGC   21.29 (+14.16%)
NVDA   212.17 (+0.00%)
MU   46.45 (-3.09%)
BABA   198.74 (-1.56%)
GE   10.99 (-0.99%)
TSLA   339.53 (+1.08%)
T   38.04 (-0.42%)
AMD   38.93 (-1.77%)
ACB   2.62 (+7.82%)
F   9.01 (-0.11%)
PRI   135.35 (-0.24%)
NFLX   302.50 (-1.58%)
BAC   33.51 (-0.48%)
GILD   66.93 (-0.22%)
DIS   146.21 (-0.98%)
S&P 500   3,135.96 (-0.32%)
DOW   27,909.60 (-0.38%)
QQQ   204.07 (-0.45%)
AAPL   266.92 (-1.40%)
FB   201.34 (+0.14%)
MSFT   151.36 (-0.26%)
GOOGL   1,342.99 (+0.27%)
AMZN   1,749.51 (-0.12%)
CGC   21.29 (+14.16%)
NVDA   212.17 (+0.00%)
MU   46.45 (-3.09%)
BABA   198.74 (-1.56%)
GE   10.99 (-0.99%)
TSLA   339.53 (+1.08%)
T   38.04 (-0.42%)
AMD   38.93 (-1.77%)
ACB   2.62 (+7.82%)
F   9.01 (-0.11%)
PRI   135.35 (-0.24%)
NFLX   302.50 (-1.58%)
BAC   33.51 (-0.48%)
GILD   66.93 (-0.22%)
DIS   146.21 (-0.98%)
S&P 500   3,135.96 (-0.32%)
DOW   27,909.60 (-0.38%)
QQQ   204.07 (-0.45%)
AAPL   266.92 (-1.40%)
FB   201.34 (+0.14%)
MSFT   151.36 (-0.26%)
GOOGL   1,342.99 (+0.27%)
AMZN   1,749.51 (-0.12%)
CGC   21.29 (+14.16%)
NVDA   212.17 (+0.00%)
MU   46.45 (-3.09%)
BABA   198.74 (-1.56%)
GE   10.99 (-0.99%)
TSLA   339.53 (+1.08%)
T   38.04 (-0.42%)
AMD   38.93 (-1.77%)
ACB   2.62 (+7.82%)
F   9.01 (-0.11%)
PRI   135.35 (-0.24%)
NFLX   302.50 (-1.58%)
BAC   33.51 (-0.48%)
GILD   66.93 (-0.22%)
DIS   146.21 (-0.98%)
Log in

NASDAQ:PTCT - PTC Therapeutics Stock Price, Forecast & News

$48.23
-0.97 (-1.97 %)
(As of 12/9/2019 04:00 PM ET)
Today's Range
$48.14
Now: $48.23
$49.75
50-Day Range
$36.28
MA: $43.11
$50.04
52-Week Range
$27.53
Now: $48.23
$50.96
Volume416,503 shs
Average Volume750,554 shs
Market Capitalization$2.97 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.9
PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular atrophy, as well as PTC596 and PTC299, a small molecule dihydrooratate dehydrogenase (DHODH) inhibitor that inhibits de novo pyrimidine nucleotide synthesis, which is in Phase 1 clinical development stage to treat cancer patients. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PTCT
CUSIPN/A
Phone908-222-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$264.73 million
Book Value$6.12 per share

Profitability

Net Income$-128,080,000.00

Miscellaneous

Employees511
Market Cap$2.97 billion
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive PTCT News and Ratings via Email

Sign-up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter.


PTC Therapeutics (NASDAQ:PTCT) Frequently Asked Questions

What is PTC Therapeutics' stock symbol?

PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."

How were PTC Therapeutics' earnings last quarter?

PTC Therapeutics, Inc. (NASDAQ:PTCT) issued its earnings results on Tuesday, October, 29th. The biopharmaceutical company reported ($1.06) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.91) by $0.15. The biopharmaceutical company earned $71.40 million during the quarter, compared to analyst estimates of $72.03 million. PTC Therapeutics had a negative net margin of 74.86% and a negative return on equity of 31.92%. The business's quarterly revenue was up 33.2% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.06) earnings per share. View PTC Therapeutics' Earnings History.

When is PTC Therapeutics' next earnings date?

PTC Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for PTC Therapeutics.

What price target have analysts set for PTCT?

10 brokerages have issued 1 year target prices for PTC Therapeutics' shares. Their forecasts range from $43.00 to $78.00. On average, they anticipate PTC Therapeutics' share price to reach $56.63 in the next twelve months. This suggests a possible upside of 17.4% from the stock's current price. View Analyst Price Targets for PTC Therapeutics.

What is the consensus analysts' recommendation for PTC Therapeutics?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for PTC Therapeutics.

Has PTC Therapeutics been receiving favorable news coverage?

News articles about PTCT stock have trended extremely negative this week, according to InfoTrie. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. PTC Therapeutics earned a news sentiment score of -4.0 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the company's share price in the immediate future. View News Stories for PTC Therapeutics.

Who are some of PTC Therapeutics' key competitors?

What other stocks do shareholders of PTC Therapeutics own?

Who are PTC Therapeutics' key executives?

PTC Therapeutics' management team includes the folowing people:
  • Dr. Stuart W. Peltz, Co-Founder, CEO & Exec. Director (Age 59)
  • Dr. Allan Steven Jacobson, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 73)
  • Ms. Christine Utter, Principal Financial Officer & Treasurer (Age 41)
  • Mr. Marcio Souza, Chief Operating Officer (Age 40)
  • Dr. Neil Almstead, Chief Technical Operations Officer (Age 52)

Who are PTC Therapeutics' major shareholders?

PTC Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include State Street Corp (3.37%), Great Point Partners LLC (3.25%), Orbimed Advisors LLC (3.18%), Pictet Asset Management Ltd. (1.89%), Scopia Capital Management LP (1.41%) and Emerald Advisers LLC (0.60%). Company insiders that own PTC Therapeutics stock include Christine Marie Utter, Marcio Souza, Mark Elliott Boulding, Michael Schmertzler, Neil Gregory Almstead and Stuart Walter Peltz. View Institutional Ownership Trends for PTC Therapeutics.

Which institutional investors are selling PTC Therapeutics stock?

PTCT stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Orbimed Advisors LLC, Scopia Capital Management LP, Sector Gamma AS, Man Group plc, Emerald Advisers LLC, Alps Advisors Inc. and Dupont Capital Management Corp. Company insiders that have sold PTC Therapeutics company stock in the last year include Christine Marie Utter, Marcio Souza, Mark Elliott Boulding and Stuart Walter Peltz. View Insider Buying and Selling for PTC Therapeutics.

Which institutional investors are buying PTC Therapeutics stock?

PTCT stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, State of New Jersey Common Pension Fund D, Handelsbanken Fonder AB, Russell Investments Group Ltd., Pictet Asset Management Ltd., California Public Employees Retirement System, Squarepoint Ops LLC and Great Point Partners LLC. View Insider Buying and Selling for PTC Therapeutics.

How do I buy shares of PTC Therapeutics?

Shares of PTCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is PTC Therapeutics' stock price today?

One share of PTCT stock can currently be purchased for approximately $48.23.

How big of a company is PTC Therapeutics?

PTC Therapeutics has a market capitalization of $2.97 billion and generates $264.73 million in revenue each year. The biopharmaceutical company earns $-128,080,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. PTC Therapeutics employs 511 workers across the globe.View Additional Information About PTC Therapeutics.

What is PTC Therapeutics' official website?

The official website for PTC Therapeutics is http://www.ptcbio.com/.

How can I contact PTC Therapeutics?

PTC Therapeutics' mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The biopharmaceutical company can be reached via phone at 908-222-7000 or via email at [email protected]


MarketBeat Community Rating for PTC Therapeutics (NASDAQ PTCT)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  472 (Vote Outperform)
Underperform Votes:  463 (Vote Underperform)
Total Votes:  935
MarketBeat's community ratings are surveys of what our community members think about PTC Therapeutics and other stocks. Vote "Outperform" if you believe PTCT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTCT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/9/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel